BioCentury | Feb 2, 2015
Company News

Astute, bioMerieux deal

Astute granted bioMerieux semi-exclusive, worldwide rights to develop and commercialize Astute’s NephroCheck test for early risk assessment of acute kidney injury on bioMerieux’s Vidas diagnostic platform. NephroCheck is an immunoassay for insulin-like growth factor (IGF)...
BioCentury | Apr 2, 2012
Company News

Vida Diagnostics management update

Vida Diagnostics Inc. , Iowa City, Iowa Business: Diagnostic Hired: Philippe Raffy as chief technology officer WIR Staff Diagnostic...
Items per page:
1 - 2 of 2
BioCentury | Feb 2, 2015
Company News

Astute, bioMerieux deal

Astute granted bioMerieux semi-exclusive, worldwide rights to develop and commercialize Astute’s NephroCheck test for early risk assessment of acute kidney injury on bioMerieux’s Vidas diagnostic platform. NephroCheck is an immunoassay for insulin-like growth factor (IGF)...
BioCentury | Apr 2, 2012
Company News

Vida Diagnostics management update

Vida Diagnostics Inc. , Iowa City, Iowa Business: Diagnostic Hired: Philippe Raffy as chief technology officer WIR Staff Diagnostic...
Items per page:
1 - 2 of 2